Medtronic Reports First Quarter Fiscal 2022 Financial Results

Strong Financial Performance on Continued Procedure Volume Recovery and Share Gains from New Product Launches

DUBLIN, Aug. 24, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its first quarter of fiscal year 2022, which endedJuly 30, 2021.

## **Key Highlights**

- Revenue of \$8.0 Billion Increased 23% Reported and 19% Organic
- GAAP Diluted EPS of \$0.56; Non-GAAP Diluted EPS of \$1.41
- Company Reiterates FY22 Revenue Guidance; Raises Lower End of FY22 EPS Guidance by5 cents

The company reported first quarter worldwide revenue of \$7.987 billion, an increase of 23% as reported and 19% on an organic basis, which excludes the \$245 million benefit of foreign currency translation. Revenue growth rates have not been adjusted for the negative impact of the extra selling week in the first quarter of last fiscal year. The company's first quarter results reflect a strong recovery from the impact of the COVID-19 pandemic on elective procedures that the company experienced in 2020. Unless otherwise stated, all revenue growth rates in this press release are stated on an organic basis, which excludes the impact of foreign currency translation.

Chairman & CEO Geoff

Martha

The company reported first quarter worldwide revenue of \$7.987 billion, an increase of 23% as reported and 19% on an organic basis, which excludes the first quarter of last fiscal year. The company's first quarter results reflect a strong recovery from the impact of the COVID-19 pandemic on elective procedures that the company experienced in 2020. Unless otherwise stated, all revenue growth rates in this press release are stated on an organic basis, which excludes the impact of foreign currency translation.

Chairman & CEO Geoff

Martha

As reported, first quarter worldwide revenue of \$7.987 billion, an increase of 23% as reported and 19% on an organic basis, which excludes the first quarter of last fiscal year. The company's first quarter results reflect a strong recovery from the impact of the COVID-19 pandemic on elective procedures that the company experienced in 2020. Unless otherwise stated, all revenue growth rates in this press release are stated on an organic basis, which excludes the size of last fiscal year. The company's first quarter results reflect a strong recovery from the impact of the COVID-19 pandemic on elective procedures that the company is first quarter results reflect a strong recovery from the impact of the COVID-19 pandemic on elective procedures that the company is first quarter results reflect a st

\$1.908 billion and \$1.41, respectively, increases of 128% and 127%, respectively.

First quarter U.S. revenue of \$4.101 billion represented 51% of company revenue and increased 22%. Non-U.S. developed market revenue of\$2.601 billion represented 33% of company revenue and increased 20% as reported and 11% organic. Emerging Markets revenue of \$1.286 billion represented 16% of company revenue and increased 31% as reported and 25% organic.

respectively. As detailed in the financial schedules included at the end of this release, first quarter non-GAAP net income and non-GAAP diluted EPS were

"Fiscal 2022 is off to a strong start with our first quarter results coming in ahead of our expectations, reflecting solid execution and continued procedure volume recovery, with most of our businesses at or above pre-COVID levels," said Geoff Martha, Medtronic chairman and chief executive officer. "In addition, we drove market share gains across a number of our businesses, including three of our largest: Cardiac Rhythm Management, Surgical Innovations, and Cranial & Spinal Technologies. Looking ahead, we have some big opportunities in front of us, with near-term milestones in both our renal denervation and surgical robotics businesses. These opportunities, combined with the broader investments we're making in our pipeline, set us up well to accelerate our top line growth."

#### Cardiovascular Portfolio

The Cardiovascular Portfolio includes the Cardiac Rhythm & Heart Failure (CRHF), Structural Heart & Aortic (SHA), and Coronary & Peripheral Vascular (CPV) divisions. Cardiovascular first quarter revenue of \$2.890 billion increased 19% as reported and 15% organic, driven by low-twenties organic growth in SHA, mid-teens organic growth in CRHF, and high-single digit growth in CPV.

- Cardiac Rhythm & Heart Failure first quarter revenue of \$1.483 billion increased 19% as reported and 15% organic. Adjusting for the discontinuation of HVAD™ System sales, CRHF revenue increased 19% organic. Cardiac Rhythm Management revenue increased in the high-teens, driven by low-double digit growth in Defibrillation Solutions and low-twenties growth in Cardiac Pacing Therapies, including low-thirties growth in Leadless Pacemakers on the continued global adoption of the Micra™ transcatheter pacing system. Cardiac Ablation Solutions revenue increased in the low-thirties on strong adoption of Arctic Front Advance™ cryoballoon catheters and consoles. Cardiovascular Diagnostics revenue grew in the low-double digits.
- Structural Heart & Aortic first quarter revenue of \$787 million increased 26% as reported and 21% organic. Structural Heart grew in the high-thirties, driven by mid-thirties growth in transcatheter aortic valves (TAVR), including high-forties TAVR growth in the United States. Cardiac Surgery increased in the high-teens. Aortic declined in the low-single digits, as the financial impact of the previously announced global recall of the Valiant Navion™ thoracic stent graft system offset low-twenties growth in abdominal aortic aneurysm (AAA) stent grafts.
- Coronary & Peripheral Vascular first quarter revenue of \$620 million increased 11% as reported and 7% organic. Coronary & Renal Denervation (CRDN) declined in the low-single digits, given the impact of previously announced coronary tenders in China. Excluding China, CRDN revenue grew in the high-single digits. Peripheral Vascular Health increased in the low-twenties, with mid-teens growth in IN.PACT™ drug-coated balloons and mid-fifties endoVenous growth on strong sales of VenaSeal™ and ClosureFast™ superficial vein products and Abre™ venous stents.

# Medical Surgical Portfolio

The Medical Surgical Portfolio includes the Surgical Innovations (SI) and the Respiratory, Gastrointestinal & Renal (RGR) divisions. Medical Surgical first quarter revenue of \$2.322 billion increased 29% as reported and 25% organic, with high-thirties organic growth in SI and mid-single digit organic growth in RGR.

- Surgical Innovations first quarter revenue of \$1.554 billion increased 44% as reported and 39% organic. The division had low-forties growth in Vessel Sealing and high-thirties growth in Advanced Stapling, driven by the continued adoption of the company's LigaSure™, Sonicision™, and Tri-Staple™ technologies. Hernia & Wound Management increased in the midthirties, with strength in sutures and hernia product lines.
- Respiratory, Gastrointestinal & Renal first quarter revenue of \$768 million increased 7% as reported and 3% organic. Patient Monitoring increased in the mid-twenties, with mid-thirties growth in the company's Nellcor™ pulse oximetry products. Respiratory Interventions decreased in the mid-twenties, with sales of ventilators declining in the low-forties as demand returns to pre-pandemic levels. Gastrointestinal revenue increased in the high-twenties on low-fifties growth in Esophageal & Gastric. Renal Care Solutions increased in the mid-single digits with strong growth in acute therapies.

# Neuroscience Portfolio

The Neuroscience Portfolio includes the Cranial & Spinal Technologies (CST), Specialty Therapies, and Neuromodulation divisions. Neuroscience first quarter revenue of \$2.204 billion increased 29% as reported and 26% organic, with high-thirties growth in Neuromodulation and Specialty Therapies and high-teens growth in CST, all on an organic basis.

- Cranial & Spinal Technologies first quarter revenue of \$1.123 billion increased 19% as reported and 17% organic. Spine & Biologics grew in the low-double digits and Neurosurgery increased in the low-twenties, as spine surgeons continue to adopt the Medtronic ecosystem of spine implants and enabling technology, including Mazor™ robotics, StealthStation™ navigation, O-arm™ imaging, and Midas Rex™ powered surgical instruments.
- Specialty Therapies first quarter revenue of \$641 million increased 42% as reported and 37% organic. Neurovascular increased in the high-single digits and ENT increased in the mid-thirties. Pelvic Health increased 134%, driven by continued strong adoption of the InterStim™ Micro sacral neuromodulation system.
- Neuromodulation first quarter revenue of \$440 million increased 40% as reported and 37% organic. Brain Modulation increased in the high-thirties, driven by the launch of the Percept™ PC deep brain stimulation system. Pain Therapies increased in the low-forties, with Targeted Drug Delivery revenue more than doubling on the backlog recovery of replacement procedures, and Pain Stim revenue growing in the mid-twenties on strong uptake of Intellis™ with DTM™ SCS therapy. Interventional grew in the low-twenties.

# **Diabetes**

Diabetes first quarter revenue of \$572 million increased 2% as reported and declined 3% organic. Diabetes quarterly revenue performance was driven by high-single digit growth in durable pumps, including strong growth in international markets on the continued launch of the MiniMed<sup>TM</sup> 780G system. This was offset by mid-teens declines in U.S. sales of consumables and continuous glucose monitoring (CGM) products.

### Guidance

The company today reiterated its revenue growth guidance and raised the lower end of its EPS guidance range for fiscal year 2022.

The company continues to expect revenue growth in its fiscal year 2022 to approximate 9% on an organic basis. If current exchange rates hold, revenue growth in fiscal year 2022 would be positively affected by approximately \$100 to \$200 million.

The company increased its fiscal year 2022 diluted non-GAAP EPS guidance from the prior range o\$5.60 to \$5.75 to the new range of\$5.65 to \$5.75, including an estimated 5 to 10 cent positive impact from foreign currency exchange versus a 10 to 15 cent positive impact previously.

"We're reiterating our revenue guidance for the year while increasing the lower end of our EPS range on the back of our first quarter results," said aren Parkhill, Medtronic chief financial officer. "We remain focused on accelerating our long-term revenue growth and generating strong returns for our shareholders. In addition to growing our dividend, we are increasing our investments at the front end of major product launches, growing our R&D spend broadly across the company, and executing disciplined tuck-in acquisitions."

#### Webcast Information

Medtronic will host a webcast today, August 24, at 8:00 a.m. EDT (7:00 a.m. CDT) to provide information about its businesses for the public, investors, analysts, and news media. This webcast can be accessed by clicking on the Investor Events link at <a href="investorrelations.medtronic.com">investors.medtronic.com</a>. Medtronic will be live tweeting during the webcast on its Newsroom Twitter account, @Medtronic. Within 24 hours of the webcast, a replay of the webcast and transcript of the company's prepared remarks will be available by clicking on the Investor Events link at <a href="investorrelations.medtronic.com">investorrelations.medtronic.com</a>.

Medtronic plans to report its fiscal year 2022 second, third, and fourth quarter results onNovember 23, 2021, February 22, 2022, and May 26, 2022, respectively. Confirmation and additional details will be provided closer to the specific event.

## Financial Schedules

The first quarter financial schedules and non-GAAP reconciliations can be viewed below. To view a printable PDF of the financial schedules and non-GAAP reconciliations, click here. To view the first quarter earnings presentation, click here.

# MEDTRONIC PLC WORLD WIDE REVENUE<sup>(1)</sup> (Unaudited)

### FIRST QUARTER(2)

		REPORTED							C	ONSTANT (	CURRENC	CY
	_						C	urrency	_			
(in millions)		FY22		FY21	Growth		Impact <sup>(4)</sup>		FY22		Grov	wth
Cardiovascular <sup>(3)</sup>	\$	2,890	\$	2,433	18.8	%	\$	96	\$	2,794	14.8	%
Cardiac Rhythm & Heart Failure		1,483		1,247	18.9			46		1,437	15.2	
Structural Heart & Aortic		787		627	25.5			28		759	21.1	
Coronary & Peripheral Vascular		620		558	11.1			22		598	7.2	
Medical Surgical		2,322		1,801	28.9			77		2,245	24.7	
Surgical Innovations		1,554		1,080	43.9			54		1,500	38.9	
Respiratory, Gastrointestinal, & Renal		768		720	6.7			23		745	3.5	
Neuroscience		2,204		1,712	28.7			47		2,157	26.0	
Cranial & Spinal Technologies		1,123		944	19.0			19		1,104	16.9	
Specialty Therapies		641		453	41.5			19		622	37.3	
Neuromodulation		440		314	40.1			10		430	36.9	
Diabetes		572		562	1.8			26		546	(2.8)	
TOTAL	\$	7,987	\$	6,507	22.7	%	\$	245	\$	7,742	19.0	%

- (1) The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum.
- (2) Fiscal year 2021 was a 53-week fiscal year, with the extra week occurring in the first fiscal month of the first quarter. While it is difficult to calculate the impact of the extra week, the Company estimates the extra week benefited the first quarter of fiscal year 2021 revenue by approximately \$360 to \$390 million.
- (3) In the fourth quarter of fiscal year 2021, the Company realigned its divisions within Cardiovascular. As a result, fiscal year 2021 results have been recast to adjust for this realignment.
- (4) The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates.

MEDTRONIC PLC
U.S.<sup>(1)(2)</sup> REVENUE
(Unaudited)

	FIRST QUARTER	
	REPORTED	
FY22	FY21	Growth

(in millions)

Cardiovascular <sup>(3)</sup>	\$ 1,420	\$ 1,206	17.7	%
Cardiac Rhythm & Heart Failure	770	672	14.6	
Structural Heart & Aortic	347	274	26.6	
Coronary & Peripheral Vascular	303	260	16.5	
Medical Surgical	990	722	37.1	
Surgical Innovations	620	400	55.0	
Respiratory, Gastrointestinal, & Renal	370	322	14.9	
Neuroscience	1,446	1,136	27.3	
Cranial & Spinal Technologies	795	692	14.9	
Specialty Therapies	360	242	48.8	
Neuromodulation	291	202	44.1	
Diabetes	245	287	(14.6)	
TOTAL	\$ 4,101	\$ 3,351	 22.4	%

- (1) U.S. includes the United States and U.S. territories.
- (2) The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum.
- (3) In the fourth quarter of fiscal year 2021, the Company realigned its divisions within Cardiovascular. As a result, fiscal year 2021 results have been recast to adjust for this realignment.

# MEDTRONIC PLC WORLD WIDE REVENUE: GEOGRAPHIC (1)(2) (Unaudited)

# FIRST QUARTER(3)

		REPORTED			CONSTANT	CURRENCY
				Currency		
(in millions)	FY22	FY21	Growth	Impact <sup>(4)</sup>	FY22	Growth
U.S.	\$ 1,420	\$ 1,206	17.7 %	\$ —	\$ 1,420	17.7 %
Non-U.S. Developed	1,003	853	17.6	72	931	9.1
Emerging Markets	467	374	24.9	24	443	18.4
Cardiovascular	2,890	2,433	18.8	96	2,794	14.8
U.S.	990	722	37.1	_	990	37.1
Non-U.S. Developed	869	719	20.9	57	812	12.9
Emerging Markets	463	359	29.0	19	444	23.7
Medical Surgical	2,322	1,801	28.9	77	2,245	24.7
U.S.	1,446	1,136	27.3	_	1,446	27.3
Non-U.S. Developed	465	376	23.7	30	435	15.7
Emerging Markets	293	199	47.2	17	276	38.7
Neuroscience	2,204	1,712	28.7	47	2,157	26.0
U.S.	245	287	(14.6)	_	245	(14.6)
Non-U.S. Developed	263	226	16.4	23	240	6.2
<b>Emerging Markets</b>	63	48	31.3	3	60	25.0
Diabetes	572	562	1.8	26	546	(2.8)
U.S.	4,101	3,351	22.4	_	4,101	22.4
Non-U.S. Developed	2,601	2,175	19.6	182	2,419	11.2
Emerging Markets	1,286	981	31.1	63	1,223	24.7
TOTAL	\$ 7,987	\$ 6,507	22.7 %	\$ 245	\$ 7,742	19.0 %

- (1) U.S. includes the United States and U.S. territories. Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries of Western Europe. Emerging Markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as previously defined.
- (2) The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum.
- (3) Fiscal year 2021 was a 53-week fiscal year, with the extra week occurring in the first fiscal month of the first quarter. While it is difficult to calculate the impact of the extra week, the Company estimates the extra week benefited the first quarter of fiscal year 2021 revenue by approximately \$360 to \$390 million.
- (4) The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates.

# MEDTRONIC PLC CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

	Three months ended						
	July 30,	July 31,					
(in millions, except per share data)	2021	2020					
Net sales	\$ 7,987	\$ 6,507					
Costs and expenses:							
Cost of products sold	2,598	2,505					
Research and development expense	750	621					
Selling, general, and administrative expense	2,547	2,417					
Amortization of intangible assets	436	440					
Restructuring charges, net	11	53					
Certain litigation charges, net	26	(88)					
Other operating expense (income), net	760	(114)					
Operating profit	859	673					
Other non-operating income, net	(111)	(82)					
Interest expense	137	171					
Income before income taxes	833	584					
Income tax provision	64	93					
Net income	769	491					
Net income attributable to noncontrolling							
interests	(6)	(4)					
Net income attributable to Medtronic	\$ 763	\$ 487					
Basic earnings per share	\$ 0.57	\$ 0.36					
Diluted earnings per share	\$ 0.56	\$ 0.36					
Basic weighted average shares outstanding	1,344.5	1,341.9					
Diluted weighted average shares outstanding	1,356.4	1,350.0					

The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum.

# MEDTRONIC PLC GAAP TO NON-GAAP RECONCILIATIONS<sup>(1)</sup>

(Unaudited)

		·		Three mo	onths ended Jul	y 30, 2021			
						Income			
		Cost of	Gross		Operating	Before	Net Income		
	Net	Products	Margin	Operating	Profit	Income	Attributable	Diluted	Effective
(in millions, except per share data)	Sales	Sold	Percent	Profit	Percent	Taxes	to Medtronic	EPS	Tax Rate
GAAP	\$ 7,987	\$ 2,598	67.5 %	\$ 859	10.8 %	\$ 833	\$ 763	\$ 0.56	7.7 %
Non-GAAP Adjustments:									
Restructuring and associated costs (2)	_	(33)	0.4	81	1.0	81	65	0.05	21.0
Acquisition-related items (3)	_	(5)	0.1	109	1.4	109	87	0.06	20.2
Certain litigation charges	_	_	_	26	0.3	26	21	0.02	19.2
(Gain)/loss on minority investments (4)	_	_	_	_	_	(31)	(29)	(0.02)	_
Medical device regulations (5)	_	(11)	0.1	21	0.3	21	17	0.01	19.0
Amortization of intangible assets	_	_	_	436	5.5	436	366	0.27	15.8
MCS impairments / costs (6)	_	(58)	0.7	726	9.1	726	564	0.42	22.3
Certain tax adjustments, net (7)	_	_	_	_	_	_	53	0.04	_
Non-GAAP	\$ 7,987	\$ 2,491	68.8 %	\$ 2,258	28.3 %	\$ 2,201	\$ 1,908	\$ 1.41	13.2 %
Currency impact	(245)	(56)	(0.3)	(47)	0.3			(0.03)	
Currency Adjusted	\$ 7,742	\$ 2,435	68.5 %	\$ 2,211	28.6 %			\$ 1.38	

									l.	ncome						
		Cost of	Gro	ss			Opera	ting	ı	Before	Net	Income				
	Net	Products	Mar	gin	Op	erating	Pro	fit	I	ncome	Attr	ibutable	-	Diluted	Effe	ctive
(in millions, except per share data)	Sales	Sold	Perc	ent	F	Profit	Perc	ent		Taxes	to M	edtronic		EPS	Tax	Rate
GAAP	\$ 6,507	\$ 2,505	61.5	%	\$	673	10.3	%	\$	584	\$	487	\$	0.36	15.9	9 %
Non-GAAP Adjustments:																
Restructuring and associated costs (2)	_	(27)	0.4			128	2.0			128		106		0.08	17.2	2
Acquisition-related items (8)	_	(2)	_			(95)	(1.5)			(95)		(67)		(0.05)	29.5	5
Certain litigation charges	_	_	_			(88)	(1.4)			(88)		(70)		(0.05)	20.5	5
(Gain)/loss on minority investments (4)	_	_	_			_	_			(10)		(10)		(0.01)	_	-
Medical device regulations (5)	_	(10)	0.2			18	0.3			18		16		0.01	11.1	
Amortization of intangible assets	_	_	_			440	6.8			440		370		0.27	15.9	)
Certain tax adjustments, net	_	_	_			_	_			_		4		_	_	-
Non-GAAP	\$ 6,507	\$ 2,466	62.1	%	\$	1,076	16.5	%	\$	977	\$	836	\$	0.62	14.0	0 %

See description of non-GAAP financial measures at the end of the earnings press release.

- (1) The data in this schedule has been intentionally rounded to the nearest million or \$0.01 for EPS figures, and, therefore, may not sum.
- (2) Associated costs include costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program and consulting expenses.
- (3) The charges primarily include acquisitions of, and certain license payments for, unapproved technology, business combination costs, and changes in fair value of contingent consideration.
- (4) We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations.
- (5) The charges represent incremental costs of complying with the new European Union medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses.
- (6) The charges relate to the Company's June 3, 2021 decision to stop the distribution and sale of the Medtronic HVAD System within the Mechanical Circulatory Support Operating Unit (MCS). Medtronic is committed to serving the needs of the approximately 4,000 patients currently implanted with the HVAD System. The charges include \$515 million of non-cash impairments, primarily related to \$409 million of intangible asset impairments, as well as \$211 million for commitments and obligations in connection with our decision, including customer support obligations, restructuring, and other associated costs.
- (7) The charges are associated with a change in the company's permanently reinvestment assertion on certain historical earnings and the amortization on previously established deferred tax assets from intercompany intellectual property transactions.
- (8) The charges primarily include business combination costs, certain license payments for unapproved technology, changes in fair value of contingent consideration, and a change in amounts accrued for certain contingent liabilities for recent acquisitions.

# MEDTRONIC PLC GAAP TO NON-GAAP RECONCILIATIONS<sup>(1)</sup>

(Unaudited)

			Т	hree months e	nded July 30, 202	1		
							Other	-
			SG&A		R&D	Other	Operating	
			Expense as		Expense as	Operating	Expense, net	Other Non-
		SG&A	a % of Net	R&D	a % of Net	Expense,	as a % of Net	Operating
(in millions)	Net Sales	Expense	Sales	Expense	Sales	net	Sales	Income, net
GAAP	\$ 7,987	\$ 2,547	31.9 %	\$ 750	9.4 %	\$ 760	9.5 %	\$ (111)
Non-GAAP Adjustments:								
Restructuring and associated costs (2)	_	(37)	(0.5)	_	_	_	_	_
Acquisition-related items (3)	_	_	_	(90)	(1.1)	(14)	(0.2)	_
Medical device regulations (4)	_	_	_	(9)	(0.1)	_	_	_
MCS impairments / costs (5)	_	_	_	_	_	(668)	(8.4)	_
Gain/(loss) on minority investments (6)	_	_	_	_	_	_	_	31
Non-GAAP	\$ 7,987	\$ 2,510	31.4 %	\$ 651	8.2 %	\$ 78	1.0 %	\$ (80)
Currency impact	(245)	(69)	0.1	(7)	0.1	(66)	(8.0)	1
Currency Adjusted	\$ 7,742	\$ 2,440	31.5 %	\$ 644	8.3 %	\$ 12	0.2 %	\$ (79)

See description of non-GAAP financial measures at the end of the earnings press release.

- (1) The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum.
- (2) Associated costs include costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program and consulting expenses.
- (3) The charges primarily include acquisitions of, and certain license payments for, unapproved technology, business combination costs, and changes in fair value of contingent consideration.

- (4) The charges represent incremental costs of complying with the new European Union medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses.
- (5) The charges relate to the Company's June 3, 2021 decision to stop the distribution and sale of the Medtronic HVAD System within the Mechanical Circulatory Support Operating Unit (MCS). Medtronic is committed to serving the needs of the approximately 4,000 patients currently implanted with the HVAD System. The charges include \$515 million of non-cash impairments, primarily related to \$409 million of intangible asset impairments, as well as \$211 million for commitments and obligations in connection with our decision, including customer support obligations, restructuring, and other associated costs.
- (6) We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations.

# MEDTRONIC PLC GAAP TO NON-GAAP RECONCILIATIONS<sup>(1)</sup>

(Unaudited)

	Th	Three months ended		ee months ended	F	iscal year
(in millions)	Ju	ıly 30, 2021	Jul	y 31, 2020		2021
Net cash provided by operating activities	\$	1,292	\$	278	\$	6,240
Additions to property, plant, and equipment		(378)		(334)		(1,355)
Free Cash Flow (2)	\$	914	\$	(56)	\$	4,885

See description of non-GAAP financial measures at the end of the earnings press release.

- (1) The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum.
- (2) Free cash flow represents operating cash flows less property, plant, and equipment additions.

# MEDTRONIC PLC CONSOLIDATED BALANCE SHEETS

(Unaudited)

(in millions)	July 30, 2021	April 30, 2021
<u>ASSETS</u>		
Current assets:		
Cash and cash equivalents	\$ 3,004	\$ 3,593
Investments	7,591	7,224
Accounts receivable, less allowances and credit losses of \$257 and \$241, respectively	5,431	5,462
Inventories, net	4,288	4,313
Other current assets	2,120	1,955
Total current assets	22,434	22,548
Property, plant, and equipment	12,808	12,700
Accumulated depreciation	(7,646)	(7,479)
Property, plant, and equipment, net	5,162	5,221
Goodwill	41,720	41,961
Other intangible assets, net	16,890	17,740
Tax assets	3,187	3,169
Other assets	2,409	2,443
Total assets	\$ 91,802	\$ 93,083
LIABILITIES AND EQUITY		
Current liabilities:		
Current debt obligations	\$ 6	\$ 11
Accounts payable	1,864	2,106
Accrued compensation	1,901	2,482
Accrued income taxes	341	435
Other accrued expenses	3,652	3,475
Total current liabilities	7,764	8,509
Long-term debt	25,958	26,378
Accrued compensation and retirement benefits	1,521	1,557

Accrued income taxes	2,262	2,251
Deferred tax liabilities	1,054	1,028
Other liabilities	1,579	1,756
Total liabilities	40,137	41,481
Commitments and contingencies		
Shareholders' equity:		
Ordinary shares— par value \$0.0001, 2.6 billion shares authorized, 1,344,671,106	and	
1,345,400,671 shares issued and outstanding, respectively	_	_
Additional paid-in capital	26,184	26,319
Retained earnings	28,511	28,594
Accumulated other comprehensive loss	(3,209)	(3,485)
Total shareholders' equity	51,486	51,428
Noncontrolling interests	178	174
Total equity	51,664	51,602
Total liabilities and equity	\$ 91,802	\$ 93,083

The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum.

# MEDTRONIC PLC CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	Three months ended					
(in millions)	July 30, 2021	July 31, 2020				
Operating Activities:						
Net income	\$ 769	\$ 491				
Adjustments to reconcile net income to net cash provided by operating activities:						
Depreciation and amortization	671	669				
Provision for doubtful accounts	15	37				
Deferred income taxes	(11)	3				
Stock-based compensation	69	70				
MCS asset impairment and inventory write-down	515	_				
Other, net	116	68				
Change in operating assets and liabilities, net of acquisitions and divestitures:						
Accounts receivable, net	(40)	(142)				
Inventories	(75)	(235)				
Accounts payable and accrued liabilities	(416)	(541)				
Other operating assets and liabilities	(321)	(142)				
Net cash provided by operating activities	1,292	278				
Investing Activities:						
Additions to property, plant, and equipment	(378)	(334)				
Purchases of investments	(2,654)	(2,045)				
Sales and maturities of investments	2,324	2,403				
Other investing activities, net	(76)	(16)				
Net cash provided by (used in) investing activities	(784)	8				
Financing Activities:						
Change in current debt obligations, net	_	(16)				
Proceeds from short-term borrowings (maturities greater than 90 days)	_	2,789				
Payments on long-term debt	(1)	(11)				
Dividends to shareholders	(846)	(778)				
Issuance of ordinary shares	111	26				
Repurchase of ordinary shares	(315)	_				
Other financing activities	(4)	(51)				
Net cash provided by (used in) financing activities	(1,055)	1,959				
Effect of exchange rate changes on cash and cash equivalents	(42)	114				
Net change in cash and cash equivalents	(589)	2,359				
Cash and cash equivalents at beginning of period	3,593	4,140				
Cash and cash equivalents at end of period	\$ 3,004	\$ 6,499				

# **Supplemental Cash Flow Information**

Cash paid for:

Income taxes	\$ 249	\$ 72
Interest	63	72

The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum.

## **About Medtronic**

Medtronic plc (<a href="www.medtronic.com">www.medtronic.com</a>), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

### FORWARD LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation and general economic conditions and other risks and uncertainties described in the company's periodic reports on file with the U.S. Securities and Exchange Commission including the most recent Annual Report on Form 10-K of the company, as filed with the U.S. Securities and Exchange Commission. In some cases, you can identify these statements by forward-looking words or expressions, such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "looking ahead," "may," "plan," "possible," "potential," "project," "should," "going to," "will," and similar words or expressions, the negative or plural of such words or expressions and other comparable terminology. Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this press release, including to reflect future events or circumstances.

## **NON-GAAP FINANCIAL MEASURES**

This press release contains financial measures, including adjusted net income, adjusted diluted EPS, and organic revenue, which are considered "non-GAAP" financial measures under applicable SEC rules and regulations. References to quarterly figures increasing, decreasing or remaining flat are in comparison to fiscal year 2021.

Medtronic management believes that non-GAAP financial measures provide information useful to investors in understanding the company's underlying operational performance and trends and to facilitate comparisons with the performance of other companies in the med tech industry. Non-GAAP net income and diluted EPS exclude the effect of certain charges or gains that contribute to or reduce earnings but that result from transactions or events that management believes may or may not recur with similar materiality or impact to operations in future periods (Non-GAAP Adjustments). Medtronic generally uses non-GAAP financial measures to facilitate management's review of the operational performance of the company and as a basis for strategic planning. Non-GAAP financial measures should be considered supplemental to and not a substitute for financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP), and investors are cautioned that Medtronic may calculate non-GAAP financial measures in a way that is different from other companies. Management strongly encourages investors to review the company's consolidated financial statements and publicly filed reports in their entirety. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the financial schedules accompanying this press release.

Medtronic calculates forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, forward-looking organic revenue growth guidance excludes the impact of foreign currency fluctuations, as well as significant acquisitions or divestitures. Forward-looking diluted non-GAAP EPS guidance also excludes other potential charges or gains that would be recorded as Non-GAAP Adjustments to earnings during the fiscal year. Medtronic does not attempt to provide reconciliations of forward-looking non-GAAP EPS guidance to projected GAAP EPS guidance because the combined impact and timing of recognition of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of financial performance.

# Contacts:

Erika Winkels Ryan Weispfenning
Public Relations Investor Relations
+1-763-526-8478 +1-763-505-4626

SOURCE Medtronic plc

Earnings Presentation (1.5 MB)

Financial Schedules
(165 KB)

Additional assets available online:

